Assessing the clinical benefit of nuclear matrix protein 22 in the surveillance of patients with nonmuscle-invasive bladder cancer and negative cytology

Cancer Statistics, 2010

(2010) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Impact of clinical factors, including a point-of-care nuclear matrix protein-22 assay and cytology, on bladder cancer detection

(2009) Yair Lotan et al.   BJU INTERNATIONAL

Decision Analysis for the Evaluation of Diagnostic Tests, Prediction Models, and Molecular Markers

(2008) Andrew J Vickers   AMERICAN STATISTICIAN

Urinary cytology and nuclear matrix protein 22 in the detection of bladder cancer recurrence other than transitional cell carcinoma

(2008) Georg C. Hutterer et al.   BJU INTERNATIONAL

Impact of risk factors on the performance of the nuclear matrix protein 22 point-of-care test for bladder cancer detection

(2008) Yair Lotan et al.   BJU INTERNATIONAL

Net reclassification improvement and decision theory

(2007) Andrew J. Vickers et al.   STATISTICS IN MEDICINE